Non-Persistence and Non-Adherence of Patients with Type 2 Diabetes Mellitus in Therapy with GLP-1 Receptor Agonists: A Retrospective Analysis
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Our main aim was to assess the level of persistence and adherence to therapy with glucagon-like peptide-1 (GLP-1) receptor agonists in type 2 diabetes mellitus (T2DM) patients in the United Kingdom (UK) and Germany, also by comparing once- (OD) with twice-a-day (BID) therapy. METHODS: We used two large retrospective datasets: a German claims dataset and the UK General Practitioner (GP)-based Clinical Practice Research Datalink (CPRD) dataset (2010-2012). All continuously insured T2DM patients with at least one outpatient/inpatient T2DM diagnosis were observed starting with the first prescription of a GLP-1 receptor agonist. Non-persistence (NP) was defined as treatment gap >90 days. Non-adherence (NA) was defined as medication possession ratio <80%, calculated during a period in which a patient continued therapy (no treatment gap >90 days) only. RESULTS: In the UK sample, 1905 T2DM patients started a treatment with GLP-1 receptor agonists (mean age: 55.5 years, 47.2% female). In the German sample, 1627 T2DM patients started a treatment with GLP-1 receptor agonists (mean age: 56.6 years, 51.4% female). Percentage of NP patients after 12 months was 29.5% in the UK and 36.4% in the German sample. In both countries, a BID treatment was associated with a higher probability to discontinue a treatment with GLP-1 receptor agonists earlier than an OD treatment (hazard ratio [HR] = 1.431 in UK and HR = 1.314 in Germany). The percentages of patients considered NA were 20.2%/20.0%/20.5% (all/OD/BID) for the UK sample, and 19.9%/19.2%/21.8% (all/OD/BID) for the German sample. CONCLUSION: NP and NA to treatment with GLP-1 receptor agonists in both UK and Germany appear to be similar. Persistence to OD treatment is higher than to BID treatment in both the UK and Germany.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GI adverse events not infrequently lead to discontinuation of drug treatment, both in randomized clinical trials (16, 17) and in real-world practice (18, 19).”
From The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications (2026) · cites this paper as [19]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The results for discontinuation by dosing schedule (weekly vs daily) diverge from other real-world studies for reasons that are unclear.”
From Real-world weight change, adherence, and discontinuation among patients with type 2 diabetes initiating glucagon-like peptide-1 receptor agonists in the UK (2022) · cites this paper as [23]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Thus, the results of this study are overall consistent with previous reports.”
From Real-world weight change, adherence, and discontinuation among patients with type 2 diabetes initiating glucagon-like peptide-1 receptor agonists in the UK (2022) · cites this paper as [23]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066
The worldwide epidemiology of type 2 diabetes mellitus—present and future perspectives
Chen, L., Magliano, D. J., & Zimmet, P. Z. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.183 · Cited by 2,227 · cited 1×
“INTRODUCTION Type 2 diabetes mellitus (T2DM) is amongst the most common chronic diseases and is a growing worldwide epidemic [1].”
BackgroundGlobal guideline for type 2 diabetes
(2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.10.001 · Cited by 1,064
Cramer, J. A., Benedict, Á., Muszbek, N., Keskinaslan, A., & Khan, Z. M. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01630.x · Cited by 487
Adherence to diabetes medication: a systematic review
Krass, I., Schieback, P., & Dhippayom, T. (2015) · Diabetic Medicine · doi:10.1111/dme.12651 · Cited by 453
A Review of Diabetes Treatment Adherence and the Association with Clinical and Economic Outcomes
Asche, C., LaFleur, J., & Conner, C. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.01.019 · Cited by 420
Determinants of Adherence to Diabetes Medications: Findings From a Large Pharmacy Claims Database
Kirkman, M. S., Rowan-Martin, M. T., Levin, R., Fonseca, V. A., Schmittdiel, J. A., Herman, W. H., & Aubert, R. E. (2015) · Diabetes Care · doi:10.2337/dc14-2098 · Cited by 388
Long-Acting Glucagon-Like Peptide 1 Receptor Agonists
Garber, A. J. (2011) · Diabetes Care · doi:10.2337/dc11-s231 · Cited by 350
GLP-1 receptor agonists: a review of head-to-head clinical studies
Trujillo, J. M., Nuffer, W., & Ellis, S. L. (2015) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018814559725 · Cited by 282
de Pablos‐Velasco, P., Parhofer, K. G., Bradley, C., Eschwège, E., Gönder-Frederick, L., Maheux, P., Wood, I., & Simon, D. (2014) · Clinical Endocrinology · doi:10.1111/cen.12119 · Cited by 218
Lund, A., Knop, F. K., & Vilsbøll, T. (2014) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2014.03.005 · Cited by 164
Dirmaier, J., Watzke, B., Koch, U., Schulz, H., Lehnert, H., Pieper, L., & Wittchen, H.-U. (2010) · Psychotherapy and Psychosomatics · doi:10.1159/000296135 · Cited by 114
New and emerging drugs and targets for type 2 diabetes: reviewing the evidence.
Miller, B. R., Nguyen, H. T., Hu, C. J.-H., Lin, C., & Nguyen, Q. P. H. (2014) · PubMed · Cited by 86
Farr, A. M., Sheehan, J. J., Curkendall, S. M., Smith, D. M., Johnston, S. S., & Kalsekar, I. (2014) · Advances in Therapy · doi:10.1007/s12325-014-0171-3 · Cited by 80
Johnston, S. S., Nguyen, H. P., Felber, E., Cappell, K. A., Nelson, J. K., Chu, B. C., & Kalsekar, I. D. (2014) · Advances in Therapy · doi:10.1007/s12325-014-0166-0 · Cited by 71
Fabunmi, R., Nielsen, L. L., Quimbo, R., Schroeder, B., Misurski, D., Wintle, M., & Wade, R. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990802715199 · Cited by 65
Zethelius, B., Gudbjörnsdottir, S., Eliasson, B., Eeg-Olofsson, K., & Cederholm, J. (2014) · European Journal of Preventive Cardiology · doi:10.1177/2047487313510893 · Cited by 65
The association between the measurement of adherence to anti-diabetes medicine and the HbA1c
Doggrell, S. A., & Warot, S. (2014) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-014-9929-6 · Cited by 59
An, J., & Nichol, M. B. (2013) · Medical Care · doi:10.1097/mlr.0b013e31829fa8ed · Cited by 57
Malmenäs, M., Bouchard, J. R., & Langer, J. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.03.021 · Cited by 43
Incretin-based therapies in prediabetes: Current evidence and future perspectives
Papaetis, G. S. (2014) · World Journal of Diabetes · doi:10.4239/wjd.v5.i6.817 · Cited by 37
Grimes, R. T., Bennett, K., Tilson, L., Usher, C., Smith, S. M., & Henman, M. C. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12573 · Cited by 33
Wilke, T., Groth, A., Mueller, S., Reese, D., Linder, R., Ahrens, S., & Verheyen, F. (2012) · The European Journal of Health Economics · doi:10.1007/s10198-012-0410-y · Cited by 26
Self-citationÖstenson, C., Matthaei, S., Reaney, M., Krarup, T., Guerci, B., Kiljański, J., Salaun-Martin, C., Sapin, H., Bruhn, D., Mathieu, C., et al. (2013) · Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy · doi:10.2147/dmso.s41827 · Cited by 14
Fabbian, F., Giorgi, A. D., Monesi, M., Pala, M., Tiseo, R., Misurati, E., Parisi, C., Volpi, R., Graziani, R., Mikhailidis, D. P., et al. (2014) · Diabetes and Vascular Disease Research · doi:10.1177/1479164114552656 · Cited by 11
Antidiabetic Treatment Patterns in a Medicare Advantage Population in the United States
Slabaugh, S. L., Xu, Y., Stacy, J. N., Baltz, J. C., MEAH, Y. A., Lian, J., Moretz, D. C., & Bouchard, J. R. (2015) · Drugs & Aging · doi:10.1007/s40266-014-0235-8 · Cited by 5
Erratum to: Antidiabetic Treatment Patterns in a Medicare Advantage Population in the United States
Slabaugh, S. L., Xu, Y., Stacy, J. N., Baltz, J. C., MEAH, Y. A., Lian, J., Moretz, D. C., & Bouchard, J. R. (2015) · Drugs & Aging · doi:10.1007/s40266-015-0317-2 · Cited by 1
Research works printed but not linked: 1
- Ostenson CG, Matthaei S, Reaney M, et al. Treatment outcomes after initiation of exenatide twice daily or insulin in clinical practice: 12-month results from CHOICE in six European countries. Diabetes Metab Syndr Obes. 2014;6:171–85.
Cited by
GLP-1 receptor agonists: an updated review of head-to-head clinical studies
Trujillo, J. M., Nuffer, W., & Smith, B. A. (2021) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018821997320 · Cited by 289
Weiss, T., Yang, L., Carr, R. D., Pal, S., Sawhney, B., Boggs, R., Rajpathak, S., & Iglay, K. (2022) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002517 · Cited by 152
Weiss, T., Carr, R. D., Pal, S., Yang, L., Sawhney, B., Boggs, R., Rajpathak, S., & Iglay, K. (2020) · Patient Preference and Adherence · doi:10.2147/ppa.s277676 · Cited by 126
Evans, M., Engberg, S., Faurby, M., Fernandes, J. D. D. R., Hudson, P., & Polonsky, W. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14603 · Cited by 90
Pasternak, B., Wintzell, V., Eliasson, B., Svensson, A.-M., Franzén, S., Gudbjörnsdottir, S., Hveem, K., Jonasson, C., Melbye, M., Svanström, H., et al. (2020) · Diabetes Care · doi:10.2337/dc19-2088 · Cited by 69
Metadata
- Authors
- Wilke, T., Mueller, S., Groth, A., Berg, B., Fuchs, A., Sikirica, M., Logie, J., Martin, A., & Maywald, U.
- Affiliations
- Wismar University of Applied Sciences (DE)
- GlaxoSmithKline (United States) (US)
- GlaxoSmithKline (United Kingdom) (GB)
- Corresponding author
- Wilke, Thomas
- Venue
- Diabetes Therapy
- Published
- 2015-12-22
- Volume
- 7
- Issue
- 1
- Pages
- 105-124
- ISSN
- 1869-6953 (ISSN-L)
- 1869-6961
- PMC
- PMC4801815
- OpenAlex
- W2211791999
- Cited by
- 41
- References
- 27
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 1 · 2022: 4 · 2021: 10 · 2020: 4 · 2019: 3 · 2018: 6 · 2017: 4 · 2016: 4
- FWCI
- 5.45
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by/4.0 (tdm)
- Locations
- Diabetes Therapy (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- GlaxoSmithKline
- Topics
- Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- type 2 diabetes, GLP-1 receptor agonists, treatment persistence, medication adherence, once-daily dosing, twice-daily dosing, treatment discontinuation, medication possession ratio, treatment gap
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.